Source: Annual Congress 2008 - Novel treatments for respiratory disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Singh, L. Smyth, Z. Borrill, L. Kent, L. Sweeney, C. Clayton, P. Linacre, M. DeSouza, R. Vessey, R. Tal-Singer (Manchester, United Kingdom; Philadelphia, PA, United States Of America). The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD. Eur Respir J 2008; 32: Suppl. 52, 2734

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011 Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005 The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005 Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages Source: Eur Respir J 2004; 23: 805-812 Year: 2004 Effect of fudosteine on mucin production Source: Eur Respir J 2008; 32: 1195-1202 Year: 2008 Effects of glucocorticoids on activation of extracellular signal-regulated kinases (ERK) in human pulmonary endothelial cells Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling Source: Eur Respir J 2005; 26: Suppl. 49, 713s Year: 2005 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 Ventilation-induced activation of the mitogen-activated protein kinase pathway Source: Eur Respir J 2002; 20: 946-956 Year: 2002 LSC 2010 Abstract: Mesothelioma cell proliferation is controlled by mitogen activated protein kinase Erk1/2 and p38 and subsequent C/EBP-β activation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 Expression of phosphorylated p38 MAPK in the lung of smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 Inhibition of GM-CSF generation in human alveolar macrophages by reduction of histone acetylation and by dephosphorylation of p38 MAPK and MKK-1 Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021